Equities research analysts predict that G1 Therapeutics Inc (NASDAQ:GTHX) will post earnings of ($0.73) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for G1 Therapeutics’ earnings. The highest EPS estimate is ($0.67) and the lowest is ($0.85). G1 Therapeutics reported earnings per share of ($0.64) in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.1%. The business is expected to announce its next earnings results on Wednesday, August 14th.
On average, analysts expect that G1 Therapeutics will report full year earnings of ($2.89) per share for the current financial year, with EPS estimates ranging from ($3.14) to ($2.67). For the next financial year, analysts anticipate that the company will report earnings of ($3.71) per share, with EPS estimates ranging from ($4.60) to ($3.26). Zacks’ EPS calculations are an average based on a survey of analysts that follow G1 Therapeutics.
G1 Therapeutics (NASDAQ:GTHX) last posted its earnings results on Thursday, May 9th. The company reported ($0.64) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.69) by $0.05.
NASDAQ:GTHX traded up $0.82 on Wednesday, reaching $26.52. The company’s stock had a trading volume of 4,852 shares, compared to its average volume of 494,523. G1 Therapeutics has a 12-month low of $13.87 and a 12-month high of $69.57. The firm has a market capitalization of $962.91 million, a price-to-earnings ratio of -10.43 and a beta of 2.68. The company has a 50 day moving average of $24.70.
Several hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers raised its holdings in G1 Therapeutics by 52.9% during the 4th quarter. Rhumbline Advisers now owns 28,246 shares of the company’s stock valued at $541,000 after buying an additional 9,772 shares during the period. BlackRock Inc. increased its position in shares of G1 Therapeutics by 6.9% in the fourth quarter. BlackRock Inc. now owns 1,963,714 shares of the company’s stock valued at $37,604,000 after buying an additional 126,892 shares in the last quarter. Northern Trust Corp increased its position in shares of G1 Therapeutics by 7.4% in the fourth quarter. Northern Trust Corp now owns 281,680 shares of the company’s stock valued at $5,393,000 after buying an additional 19,360 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of G1 Therapeutics in the fourth quarter valued at approximately $1,570,000. Finally, Geode Capital Management LLC increased its position in shares of G1 Therapeutics by 10.3% in the fourth quarter. Geode Capital Management LLC now owns 279,063 shares of the company’s stock valued at $5,344,000 after buying an additional 26,098 shares in the last quarter. Hedge funds and other institutional investors own 73.35% of the company’s stock.
About G1 Therapeutics
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Featured Article: S&P 500 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.